Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

Background/Aims: In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically fo...

Full description

Bibliographic Details
Main Authors: Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2017-10-01
Series:Intestinal Research
Subjects:
Crohn disease
Adalimumab
Withdraw
Online Access:https://doi.org/10.5217/ir.2017.15.4.487

Internet

https://doi.org/10.5217/ir.2017.15.4.487

Similar Items